Real-world outcomes of tandem ASCT in newly diagnosed multiple myeloma patients with standard risk features: a single-center analysis

Bone Marrow Transplant. 2024 Nov;59(11):1625-1627. doi: 10.1038/s41409-024-02404-1. Epub 2024 Aug 26.

Andrea Poveda-García^#¹, Estela Ruiz^#¹, María José Moreno^{1

2}, Ignacio Español^{1

2}, Andrés Sánchez-Salinas^{1

2}, Ana María García-Hernández^{1

2}, Miguel Blanquer^{1

2}, Inmaculada Martínez^{1

2}, María Sánchez-Villalobos^{1

2}, María Carmen García Garay¹, Eduardo Salido^{1

2}, Ángela Heredia¹, Begoña Navarro-Almenzar¹, Jorge Monserrat¹, José Antonio Sánchez-Salas¹, Antonio José Martínez-Mellado^{1

2}, Alfredo Minguela^{3

4}, José Antonio Campillo^{3

4}, Ruth López-Hernández^{3

4}, José Antonio Galián^{3

4}, José M Moraleda^{1

2}, Vanessa Roldán^{1

2}, Valentín Cabañas^{5

6}

¹ Department of Hematology, Virgen de la Arrixaca University Hospital, Murcia, Spain.
² Stem Cell Transplant and Advanced Therapies Unit. IMIB-Pascual Parrilla. University of Murcia, Murcia, Spain.
³ Department of Immunology, Virgen de la Arrixaca University Hospital, Murcia, Spain.
⁴ Immunology and immunotolerance in transplants and immune-based diseases. IMIB-Pascual Parrilla. University of Murcia, Murcia, Spain.
⁵ Department of Hematology, Virgen de la Arrixaca University Hospital, Murcia, Spain. valentin.cabanas@gmail.com.
⁶ Stem Cell Transplant and Advanced Therapies Unit. IMIB-Pascual Parrilla. University of Murcia, Murcia, Spain. valentin.cabanas@gmail.com.

^# Contributed equally.

No abstract available

Publication types